NASDAQ:SYRS

Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis

Syros Pharmaceuticals logo
$0.0001 0.00 (0.00%)
As of 02:53 PM Eastern

About Syros Pharmaceuticals Stock (NASDAQ:SYRS)

Advanced

Key Stats

Today's Range
$0.0001
▼
$0.0001
50-Day Range
N/A
52-Week Range
$0.0001
▼
$0.0120
Volume
9,653 shs
Average Volume
15,104 shs
Market Capitalization
$2.68 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Syros Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines that influence gene expression—the processes that control how genes are turned on or off. The company was founded in 2012 and is based in Cambridge, Massachusetts.

Its drug-development work has focused primarily on cancer and blood disorders. Syros has advanced tamibarotene, a selective retinoic acid receptor alpha agonist investigated for certain forms of acute myeloid leukemia and myelodysplastic syndrome. Its research portfolio has also included other small-molecule candidates for hematologic cancers and solid tumors.

Syros has used genomic and molecular research to identify disease-related patterns of gene activity and guide the development of potential treatments. Its programs have been investigational; the company’s candidates should not be described as approved therapies.

AI Generated. May Contain Errors.

Receive SYRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SYRS Stock News Headlines

Your book is inside
Blane Markham and the Markham Trading Team are giving readers a limited window to download their options strategy guide, titled How To Turn $100 Options Into $1,000 Gains, before it moves behind a paywall. The guide walks through options trading concepts the team uses in its own research and education materials. Once the paywall goes up, free access ends for good.tc pixel
Syros Pharmaceuticals trading resumes
Syros Pharmaceuticals Plans to Wind Down Operations
See More Headlines

SYRS Stock Analysis - Frequently Asked Questions

Syros Pharmaceuticals' stock was trading at $0.0004 at the beginning of the year. Since then, SYRS shares have decreased by 75.0% and is now trading at $0.0001.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings data on Thursday, October, 31st. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.08.
Read the conference call transcript
.

Shares of Syros Pharmaceuticals reverse split before market open on Monday, September 19th 2022.The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Syros Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Tesla (TSLA), Abeona Therapeutics (ABEO) and Sangamo Therapeutics (SGMO).

Company Calendar

Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SYRS
CIK
1556263
Fax
N/A
Employees
68
Year Founded
2012

Profitability

EPS (Trailing Twelve Months)
($3.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$164.57 million
Net Margins
N/A
Pretax Margin
-25,275.20%
Return on Equity
-3,369.56%
Return on Assets
-97.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.25
Quick Ratio
2.25

Sales & Book Value

Annual Sales
$386 thousand
Price / Sales
0.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.79 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
26,832,000
Free Float
23,542,000
Market Cap
$2.68 thousand
Optionable
No Data
Beta
1.31

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:SYRS) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners